BioMarin Pharmaceuticals BMRN Return on equity

Return on equity at other companies

Sarepta Therapeutics, Inc.SRPT

-9.3%+2,662pp

Zevra Therapeutics, Inc.ZVRA

34.8%+31.3pp

Agios PharmaceuticalsAGIO

-34.3%—

RegenxbioRGNX

-137.6%-817pp

Tyra Biosciences, Inc.TYRA

-36.9%+21.1pp

Crinetics PharmaceuticalsCRNX

-39.2%+14.5pp

FAQ

What is BioMarin Pharmaceuticals's return on equity?

BioMarin Pharmaceuticals (BMRN) reported return on equity of 9.1% in Q3 2025.

How has BioMarin Pharmaceuticals's return on equity changed year-over-year?

BioMarin Pharmaceuticals's return on equity increased by 45.1% year-over-year, from 6.3% to 9.1%.

What is the long-term trend for BioMarin Pharmaceuticals's return on equity?

Over 4 years (2020 to 2024), BioMarin Pharmaceuticals's return on equity has grown at a -23.6% compound annual growth rate (CAGR), from 23.6% to 8%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.